RU2420312C2 - Усовершенствования, касающиеся везикул внешней мембраны менингококков - Google Patents

Усовершенствования, касающиеся везикул внешней мембраны менингококков Download PDF

Info

Publication number
RU2420312C2
RU2420312C2 RU2007111838/15A RU2007111838A RU2420312C2 RU 2420312 C2 RU2420312 C2 RU 2420312C2 RU 2007111838/15 A RU2007111838/15 A RU 2007111838/15A RU 2007111838 A RU2007111838 A RU 2007111838A RU 2420312 C2 RU2420312 C2 RU 2420312C2
Authority
RU
Russia
Prior art keywords
omv
seropodotype
meningococci
meningococcal
composition
Prior art date
Application number
RU2007111838/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2007111838A (ru
Inventor
Филипп ОСТЕР (IT)
Филипп ОСТЕР
Рино РАППУОЛИ (IT)
Рино РАППУОЛИ
Марияграция ПИЦЦА (IT)
Марияграция ПИЦЦА
Original Assignee
Новартис Вэксинс Энд Диагностикс С.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Вэксинс Энд Диагностикс С.Р.Л. filed Critical Новартис Вэксинс Энд Диагностикс С.Р.Л.
Publication of RU2007111838A publication Critical patent/RU2007111838A/ru
Application granted granted Critical
Publication of RU2420312C2 publication Critical patent/RU2420312C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
RU2007111838/15A 2004-09-03 2005-09-05 Усовершенствования, касающиеся везикул внешней мембраны менингококков RU2420312C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0419627.5A GB0419627D0 (en) 2004-09-03 2004-09-03 Immunogenic bacterial vesicles with outer membrane proteins
GB0419627.5 2004-09-03

Publications (2)

Publication Number Publication Date
RU2007111838A RU2007111838A (ru) 2008-10-10
RU2420312C2 true RU2420312C2 (ru) 2011-06-10

Family

ID=33156002

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007111838/15A RU2420312C2 (ru) 2004-09-03 2005-09-05 Усовершенствования, касающиеся везикул внешней мембраны менингококков

Country Status (13)

Country Link
US (1) US8808711B2 (cg-RX-API-DMAC7.html)
EP (1) EP1784213B1 (cg-RX-API-DMAC7.html)
JP (2) JP2008511608A (cg-RX-API-DMAC7.html)
CN (2) CN101115501A (cg-RX-API-DMAC7.html)
AU (1) AU2005278896B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0514883A (cg-RX-API-DMAC7.html)
CA (1) CA2578588A1 (cg-RX-API-DMAC7.html)
ES (1) ES2527859T3 (cg-RX-API-DMAC7.html)
GB (1) GB0419627D0 (cg-RX-API-DMAC7.html)
MX (1) MX2007002633A (cg-RX-API-DMAC7.html)
NZ (1) NZ553521A (cg-RX-API-DMAC7.html)
RU (1) RU2420312C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006024946A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
MX2010012999A (es) * 2008-05-30 2012-03-07 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
GB0822634D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
AU2015289193A1 (en) * 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Meningococcus vaccines
MX2017000776A (es) 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
KR101742236B1 (ko) * 2014-10-29 2017-05-31 인하대학교 산학협력단 쯔쯔가무시병에 대한 면역 조성물 및 이의 제조방법
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药(苏州)股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105890A2 (en) * 2002-06-13 2003-12-24 Glaxosmithkline Biologicals S.A. Vaccine composition
WO2004079977A2 (en) * 2003-03-03 2004-09-16 Interdigital Technology Corporation Optimizing multi-user detection

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
DK0710118T3 (da) 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
JP2001510169A (ja) 1997-07-17 2001-07-31 ノース アメリカン ワクチン, インコーポレイテッド B型髄膜炎菌性ポーリンおよびH.influenzae多糖体を含む免疫原性結合体
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7628995B2 (en) 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
ES2337309T5 (es) * 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105890A2 (en) * 2002-06-13 2003-12-24 Glaxosmithkline Biologicals S.A. Vaccine composition
WO2004079977A2 (en) * 2003-03-03 2004-09-16 Interdigital Technology Corporation Optimizing multi-user detection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ESTER D. et al. Immunogenicity and safety of hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age, Vaccine, 2000, v.18, №15, p.1456-1466, abstract. SEXTON С.et al., The New Zealand meningococcal vaccine strategy: A tailor-made vaccine to combat a devastating epidemic, The New Zealand Medical Journal, 2004, v.117, №1200, доступно он-лайн://www.nzma.org.nz/journal/117-1200/1015. BAKKE H. et al. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infection and Immunity, 2001, v.69, №6, p.5010-5015. *

Also Published As

Publication number Publication date
WO2006024946A2 (en) 2006-03-09
AU2005278896B2 (en) 2011-12-22
NZ553521A (en) 2010-01-29
RU2007111838A (ru) 2008-10-10
CN101115501A (zh) 2008-01-30
JP2008511608A (ja) 2008-04-17
US20080063665A1 (en) 2008-03-13
JP2011236254A (ja) 2011-11-24
BRPI0514883A (pt) 2008-06-24
CA2578588A1 (en) 2006-03-09
EP1784213A2 (en) 2007-05-16
GB0419627D0 (en) 2004-10-06
US8808711B2 (en) 2014-08-19
MX2007002633A (es) 2007-05-15
WO2006024946A3 (en) 2006-11-30
EP1784213B1 (en) 2014-10-29
ES2527859T3 (es) 2015-01-30
CN101862451A (zh) 2010-10-20
AU2005278896A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
US8808711B2 (en) Meningococcal outer membrane vesicles
US10336794B2 (en) Immunogenic bacterial vesicles with outer membrane proteins
RU2475496C2 (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
US20130022633A1 (en) MENINGOCOCCAL fHBP POLYPEPTIDES
RU2362784C2 (ru) Гипо- и гиперацетилированные менингококковые капсульные сахариды
US20130071422A1 (en) Adjuvanted vaccines for serogroup b meningococcus
US20110262484A1 (en) Outer membrane vesicle prime-protein boost vaccine
EP1945249A2 (en) Compositions with antigens adsorbed to calcium phosphate
ES2727798T3 (es) Polipéptidos de FHPP meningocócicos
AU2016273825A1 (en) Modified meningococcal fHBP polypeptides
MX2007004035A (es) Vesciculas bacterianas inmunogenicas con proteinas de membrana externa

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140906